Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
Successful and Safe Reinstitution of Chemotherapy for Pancreatic Cancer after COVID-19
Kazumasa NagaiKatsuya KitamuraYuji HiraiDaisuke NutaharaHironori NakamuraJunichi TairaYubu MatsueMasakazu AbeMiho KikuchiTakao Itoi
Author information
JOURNAL OPEN ACCESS

2021 Volume 60 Issue 2 Pages 231-234

Details
Abstract

Cancer patients are regarded as highly vulnerable to severe acute respiratory syndrome coronavirus (SARS-CoV)-2. However, little is known regarding how cancer treatments should be restarted for cancer patients after coronavirus disease (COVID)-19. We herein report a pancreatic cancer case in which chemotherapy was able to be reinstituted after COVID-19. The patient was a 67-year-old man diagnosed with pancreatic cancer. On day 7 after first chemotherapy, he was infected with COVID-19. A SARS-CoV-2 test was negative after one month of treatment, and we reinstituted chemotherapy. The patient has received three cycles of chemotherapy without recurrence of COVID-19. It may be feasible to reinstitute chemotherapy for cancer patients after a negative SARS-CoV-2 test.

Information related to the author
© 2021 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top